Virkningen af Tasigna blev undersøgt i to hovedundersøgelser med i alt 439 patienter med CML, hvor imatinib ikke tolereredes eller ikke længere virkede på sygdommen.
The effectiveness of Tasigna was studied in two main studies involving a total of 439 patients with CML, who could not tolerate imatinib or whose disease had stopped responding to it.